Dual blockade of IL-4 and IL-13 with dupilumab reduces severity of type 2 inflammatory immune-related adverse events

Lee, C; Chung, W; Chen, C

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023; 143 (5): S84